Massimo Lazzari, MD, discusses findings from an analysis of the urinary microbiota in patients with bladder cancer.
Massimo Lazzari, MD, Humanitas Clinical Research Hospital, discusses findings from an analysis of the urinary microbiota in patients with bladder cancer.
Eleven patients were evaluated as age-matched controls and about 50 patients with bladder cancer, Lazzari says. Initially, investigators tried to identify a difference between normal patients and patients with bladder cancer, which led to the discovery ofheterogeneityin the urinary microbiota.
Investigators found various species, such as Actinobacteria, Bacteroidetes, Firmicutes, and Proteobacteria, Lazzari says. They also found a decrease in a specific species, like Ruminococcus which is a very important bacteria for anti-inflammatory activity. A decrease of Ruminoccoccus of bowel inflammation was observed, and the same was found in the bladder.
Finally, Lazzari noted that there was a correlation between the stage of bladder cancer with Sphingobacteriaceae. For example, there was an increase in Corynebacterium in higher grade, higher stage bladder cancer.
<< For more information regarding this study and its findings in patients with bladder cancer
FDA Approves Nogapendekin Alfa Inbakicept for BCG-Unresponsive NMIBC Carcinoma In Situ
April 22nd 2024Patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer carcinoma in situ now have a new treatment option following the FDA’s approval of nogapendekin alfa.
Read More
FDA Accepts IND for UGN-103 in Low-Grade Intermediate-Risk NMIBC
April 15th 2024An investigational new drug application for UGN-103 was accepted by the FDA. A phase 3 study to assess the safety and efficacy of the agent in low-grade intermediate-risk non-muscle invasive bladder cancer is anticipated.
Read More